NCT05364164CompletedPhase 1
A Phase I, Randomized, Open-Label, Single-Dose, Crossover Study to Evaluate Food Effect on the Pharmacokinetics and Safety of CT-L01 After Oral Administration in Healthy Volunteers
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Celltrion
- Enrollment
- 24
- Locations
- 1
- Primary Endpoint
- AUClast (Area under the plasma concentration-time curve)
Study Overview
Brief Summary
This is a phase 1, randomized, open-label, single-dose, crossover, single-center study to evaluate food effect on the pharmacokinetics and safety of CT-L01 after oral administration in healthy volunteers.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 19 Years to 50 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy subject aged 19 to 50 years, at screening
- •A subject who weighs 50 kg or more at the screening visit and has a body mass index (BMI) of 18.0~30.0 kg/m2
- •A subject who is judged to be eligible to participate by the results of screening tests (vital signs, clinical laboratory tests, 12-lead ECG, etc.) by the principal investigator within 28 days before the first administration of the investigational drug
- •A subject and their partner who agree to use a medically appropriate method of contraception to exclude potential of pregnancy and not to provide sperm or ova from the first dose to 28 days after the last dose of the investigational drug
- •A subject who voluntarily signs the consent form after hearing and understanding the purpose and content of this study, thge characteristics of the investigational drugs, expected adverse reactions, and etc.
Exclusion Criteria
- •A subject who has a history or present symptoms of clinically significant liver, kidney, nervous system, respiratory system, digestive system, endocrine system, blood/tumor, urinary system, cardiovascular system, musculoskeletal disease, or psychiatric disease
- •A subject who has an acute illness within 28 days prior to the first dose of investigational drug
- •A subject who has a history of gastrointestinal surgery that may affect drug absorption (except simple appendectomy or hernia surgery) or has gastrointestinal diseases
- •A subject who has taken drugs that induce or inhibit drug metabolizing enzymes such as barbiturates within 1 month prior to the first administration
- •A subject who has participated in other clinical trials or bioequivalence studies within 6 months prior to the first dose of the investigational drug
- •A subject who is judged unsuitable to participate in this study by the principal investigator
Arms & Interventions
CT-L01 12.5/1,000 mg FDC Tablet, dosing under fasting condition
Experimental
Alogliptin Benzoate 12.5 mg/Metformin HCl XR 1,000 mg, FDC Tablet, dosing under fasting condition
Intervention: CT-L01 12.5/1,000 mg (Drug)
CT-L01 12.5/1,000 mg FDC Tablet, dosing under fed condition
Experimental
Alogliptin Benzoate 12.5 mg/Metformin HCl XR 1,000 mg, FDC Tablet, dosing after high-fat meal
Intervention: CT-L01 12.5/1,000 mg (Drug)
Outcomes
Primary Outcomes
AUClast (Area under the plasma concentration-time curve)
Time Frame: Pre-dose(0.00), 0.25, 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00, 48.00, and 72.00 hours
Cmax (Peak Plasma Concentration)
Time Frame: Pre-dose(0.00), 0.25, 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00, 48.00, and 72.00 hours
Secondary Outcomes
- t1/2 (Half-life)(Pre-dose(0.00), 0.25, 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00, 48.00, and 72.00 hours)
- AUCinf (Area under the plasma concentration-time curve from time 0 to infinity)(Pre-dose(0.00), 0.25, 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00, 48.00, and 72.00 hours)
- AUClast/AUCinf(Pre-dose(0.00), 0.25, 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00, 48.00, and 72.00 hours)
- Tmax (Time of peak plasma concentration)(Pre-dose(0.00), 0.25, 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00, 48.00, and 72.00 hours)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Drug Drug Interaction Study Of Crizotinib With Esomeprazole.HealthyNCT01549574Pfizer16
Completed
Phase 1
A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic ImpairmentHepatic ImpairmentNCT03713242Idorsia Pharmaceuticals Ltd.32
Completed
Phase 1
The Effect of Reduced Liver Function on Selatogrel PharmacokineticsHealthy SubjectsHepatic ImpairmentNCT04406896Viatris Innovation GmbH24
Completed
Phase 1
Clinical Trial to Assess the Effect of Food on the Pharmacokinetics of YHD1119 in Healthy VolunteersPeripheral Neuropathic PainNCT03191136Yuhan Corporation24
Completed
Phase 1
A Phase I Study to Determine the Effect of Food on the Pharmacokinetic Profile of BPI-7711NSCLCNCT04135820Beta Pharma, Inc.16